GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) was down 3% on Tuesday . The company traded as low as $22.02 and last traded at $22.68. Approximately 169,891 shares were traded during mid-day trading, a decline of 56% from the average daily volume of 383,749 shares. The stock had previously closed at $23.38.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on WGS shares. TD Cowen raised their target price on shares of GeneDx from $14.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, April 30th. BTIG Research upped their target price on shares of GeneDx from $15.00 to $19.00 and gave the company a "buy" rating in a report on Tuesday, April 30th. Finally, The Goldman Sachs Group raised their price target on GeneDx to $11.00 and gave the stock a "neutral" rating in a report on Monday, April 15th.
Read Our Latest Report on WGS
GeneDx Stock Down 8.7 %
The company has a quick ratio of 2.99, a current ratio of 3.22 and a debt-to-equity ratio of 0.25. The firm's fifty day simple moving average is $11.83 and its 200-day simple moving average is $6.27. The company has a market cap of $557.66 million, a PE ratio of -4.12 and a beta of 2.17.
GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Tuesday, February 20th. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.01. GeneDx had a negative return on equity of 36.23% and a negative net margin of 60.86%. The firm had revenue of $57.42 million for the quarter, compared to analysts' expectations of $57.00 million. As a group, equities research analysts expect that GeneDx Holdings Corp. will post -2.02 earnings per share for the current fiscal year.
Insider Activity
In other news, Director Casdin Capital, Llc bought 40,000 shares of the firm's stock in a transaction that occurred on Monday, March 4th. The shares were purchased at an average price of $8.74 per share, for a total transaction of $349,600.00. Following the completion of the transaction, the director now owns 2,702,609 shares in the company, valued at $23,620,802.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other GeneDx news, Director Casdin Capital, Llc purchased 40,000 shares of the firm's stock in a transaction on Monday, March 4th. The shares were purchased at an average cost of $8.74 per share, with a total value of $349,600.00. Following the purchase, the director now owns 2,702,609 shares in the company, valued at $23,620,802.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Katherine Stueland sold 8,559 shares of GeneDx stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $10.59, for a total value of $90,639.81. Following the completion of the sale, the chief executive officer now owns 66,698 shares of the company's stock, valued at approximately $706,331.82. The disclosure for this sale can be found here. Insiders sold a total of 21,249 shares of company stock valued at $228,370 over the last 90 days. Insiders own 28.10% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of WGS. Thompson Davis & CO. Inc. boosted its position in shares of GeneDx by 20.8% in the first quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company's stock worth $220,000 after buying an additional 4,150 shares during the period. PFG Investments LLC purchased a new position in GeneDx in the 1st quarter worth approximately $95,000. Vanguard Group Inc. grew its position in GeneDx by 4.2% in the first quarter. Vanguard Group Inc. now owns 707,612 shares of the company's stock valued at $6,460,000 after acquiring an additional 28,678 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of GeneDx by 14.1% during the third quarter. HighTower Advisors LLC now owns 237,948 shares of the company's stock valued at $865,000 after purchasing an additional 29,361 shares during the period. Finally, Pathstone Family Office LLC lifted its position in shares of GeneDx by 262.2% during the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company's stock worth $198,000 after purchasing an additional 39,327 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company's stock.
GeneDx Company Profile
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
